AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Lilly’s $2.25 billion pact with Profluent signals a new phase in AI-powered genetic medicine
Eli Lilly’s multibillion-dollar deal with AI biotech Profluent underscores how seriously large pharma is now betting on generative biology. The partnership suggests the next frontier for AI drug discovery may not be small-molecule screening alone, but programmable biology and genetic medicine design.
Reuters frames Lilly-Insilico agreement as evidence AI drug discovery is becoming a sourcing channel
Reuters reports that Eli Lilly has extended its partnership with Insilico Medicine for AI-powered drug discovery, reinforcing the idea that major drugmakers now view AI firms as external sources of pipeline opportunities. The significance lies in AI moving from service function to asset origination channel.
Insilico Deepens CNS Ambitions With Tenacia Expansion Worth Up to $94.75 Million
Insilico Medicine and Tenacia Biotechnology have expanded their AI-driven CNS partnership in a deal valued at up to $94.75 million. The agreement underscores both sustained investor interest in AI-enabled pipelines and the continued appeal of high-need neuropsychiatric and neurological targets despite their development risk.
Xaira’s Next Act Will Test Whether Mega-Financing Can Build a New Kind of AI Biotech
After raising nearly $1 billion, Xaira Therapeutics is entering the phase where capital must translate into durable scientific and organizational advantage. The company’s next moves will be watched as a referendum on whether AI-native biotech platforms can justify venture funding at exceptional scale.
Earendil’s $787 Million Raise Signals Investor Appetite for AI Biologics at Scale
Earendil has raised $787 million to expand an AI-led biologics strategy, one of the largest recent financings in computational biotech. The round underscores that investors still back platform stories when they target large, high-value therapeutic categories and present a path from model development to drug creation.
Xaira’s Next Act Shows the Market Wants AI Biotech Platforms With Product Intent, Not Just Capital
Fresh reporting on Xaira after its nearly $1 billion raise suggests the company is entering the harder phase of the AI-biotech story: turning exceptional financing into a coherent R&D engine. The broader lesson is that investors now expect AI-native biotech companies to demonstrate scientific focus and program strategy, not merely computational ambition.
Ternary Therapeutics Funding Suggests Investors Still Like Focused AI Biotech Stories
Ternary Therapeutics has raised €4.1 million for an AI-driven molecular glue drug-discovery platform, showing that investor appetite remains for narrower, mechanism-focused AI biotech plays. The financing is small relative to mega-round platform companies, but it may be more representative of how capital is now being allocated: selectively, around differentiated biology and clear use cases.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.